Compounds studied for metabolic, ranked by the strength of the evidence — strongest at the top, research-grade and disappointing below. Grades reflect the evidence, not marketing. This is a neutral reference; nothing here is a recommendation to use, and no compound is offered for sale.
Liraglutide is the pioneer GLP-1 — the first in wide use and the first approved for obesity (Saxenda, 2014), the drug that opened the field for semaglutide and tirzepatide.
Mazdutide is a GLP-1 / glucagon dual-agonist peptide — the same mechanism as Survodutide (#6) — but designed as an oxyntomodulin analog and co-developed by Innovent and Eli Lilly.
NAD⁺ is a fundamental coenzyme (not a peptide) that powers energy metabolism, DNA repair, and the sirtuin "longevity" enzymes — and declines with age, which is the basis of a…
Pramlintide is the original amylin analog and a long-approved drug (Symlin, FDA 2005) — a synthetic version of amylin, the satiety/glucose hormone co-released with insulin.
Semaglutide is a GLP-1 receptor agonist and one of the most-prescribed medicines in the world — FDA-approved for type-2 diabetes (Ozempic), obesity (Wegovy) and oral T2D…
Tesamorelin is a stabilized 44-amino-acid GHRH analog and the only GHRH analog with a current FDA approval (as Egrifta, for HIV-associated lipodystrophy since 2010).
Tirzepatide is a dual GIP/GLP-1 agonist and, in the only head-to-head obesity trial (SURMOUNT-5), produced greater weight loss than semaglutide (−20.2% vs −13.7%).
Amycretin is Novo Nordisk's first-in-class unimolecular GLP-1 + amylin agonist — the CagriSema concept in a single molecule, developed as both a pill and a weekly injection.
Bimagrumab is a monoclonal antibody that blocks the activin type II receptors, producing a unique effect — fat loss with simultaneous muscle gain.
Cagrilintide is a long-acting amylin analog — a genuinely different mechanism from the GLP-1 drugs, acting on amylin/calcitonin receptors in the brainstem.
Eloralintide (Lilly's LY3841136) is a once-weekly, selective amylin-receptor agonist — and it closes the register's amylin story with the class's strongest monotherapy data yet.
Orforglipron is the first oral small-molecule GLP-1 — a non-peptide pill, taken anytime without food/water restrictions, that in Phase 3 delivered semaglutide-level weight loss…
Petrelintide is a long-acting, once-weekly amylin analog (Zealand Pharma, partnered with Roche in a $5.3 billion deal) — the modern realization of the amylin approach that…
Retatrutide is Eli Lilly's investigational triple GLP-1/GIP/glucagon agonist ("triple-G"), which in Phase 3 (TRIUMPH-1) produced the deepest weight loss of any obesity candidate…
Survodutide is an investigational GLP-1 / glucagon dual-agonist peptide (weekly injection) from Boehringer Ingelheim and Zealand Pharma.
Tesofensine (NS-2330) is a small-molecule triple monoamine reuptake inhibitor — it raises dopamine, norepinephrine, and serotonin at once — and its story is a gem of…
Humanin is the founding mitochondrial-derived peptide — a 24-amino-acid signal encoded in mitochondrial DNA, discovered in 2001 from an Alzheimer's-resistant neuron.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide, encoded in mtDNA and discovered in 2015, that regulates metabolism largely through the AMPK pathway.
Pemvidutide (Altimmune's ALT-801) is a once-weekly, balanced 1:1 glucagon/GLP-1 dual agonist — and it closes the register's glucagon-dual cluster with a distinctive liver-first…
ATX-304 is a direct pan-AMPK activator — it switches on AMP-activated protein kinase, the cell's central energy sensor, turning up fat-burning and glucose uptake and turning down…
BAM15 is a mitochondrial uncoupler — a protonophore that dissipates the proton gradient across the inner mitochondrial membrane, so energy is released as heat instead of stored…
5-Amino-1MQ is a small-molecule NNMT inhibitor (not a peptide) studied for fat loss through a mechanism quite different from GLP-1 drugs: instead of curbing appetite, it acts…
Adipotide (FTPP) is a synthetic two-part peptide that works unlike any other fat-loss compound here: instead of curbing appetite or tweaking metabolism, it selectively destroys…
AICAR (Acadesine) is a small-molecule AMPK activator — not a peptide — and the original "exercise in a pill." By entering cells and mimicking AMP (as ZMP), it switches on AMPK,…
AOD-9604 is a synthetic fragment of growth hormone's fat-burning tail (residues 176-191, stabilised with a tyrosine and a disulfide bridge), engineered by Metabolic…
Apelin is an endogenous peptide and the natural ligand of the APJ receptor, a G-protein-coupled receptor closely related to the angiotensin II receptor.
SLU-PP-332 is a small-molecule ERR (estrogen-related receptor) agonist — an "exercise mimetic" designed to switch on the muscle's aerobic-exercise gene program without exercise.
SLU-PP-915 is a small-molecule pan-ERR agonist — an "exercise mimetic" — and the orally-active successor to SLU-PP-332 (#60) from the same lab (Thomas Burris).
Ranking is by evidence grade (A–F), the same ceiling shown on each compound page — not by popularity or margin. No dosing, reconstitution, or administration is given anywhere on Vallydia. See each entry for its full evidence table and legal status by region.
A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.